Brief: Celldex Announces Upcoming Late Breaking Oral Presentation Of 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Inducible Urticaria At Acaai 2024
25/10/2024 14:17
Oct 25 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX ANNOUNCES UPCOMING LATE BREAKING ORAL PRESENTATION
OF 12
WEEK RESULTS FROM BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC
INDUCIBLE URTICARIA AT ACAAI 2024
Source text for Eikon: ID:nGNX91sWjX
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials